ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
향후 몇 년동안 카르티노이드 종양 시장은 이 질환에 대한 인식이 높아지고 전 세계 의료비 지출이 증가함에 따라 변화할 것으로 예상됩니다.
기업과 연구기관들은 카르티노이드 종양 연구개발에 영향을 미칠 수 있는 과제를 평가하고 기회를 모색하기 위해 노력하고 있습니다. 개발 중인 치료법은 질병을 치료/개선하기 위한 새로운 접근법에 초점을 맞추었습니다. 주요 기업들이 카르티노이드 종양 치료제 개발에 참여하고 있습니다. 새로운 치료법의 등장은 카르티노이드 종양 시장에 큰 영향을 미칠 것으로 예상됩니다.
이 보고서는 주요 7개국의 카르티노이드 종양 시장을 조사했으며, 시장 개요와 함께 역학, 환자 동향, 새로운 치료법, 2034년까지 시장 규모 예측, 미충족 의료 수요 등의 정보를 제공합니다.
목차
제1장 주요 인사이트
제2장 카르티노이드 종양 주요 요약
제3장 카르티노이드 종양 경쟁 정보 분석
제4장 카르티노이드 종양 : 시장 개요
제5장 카르티노이드 종양 : 질환 배경과 개요
서론
징후와 증상
병태생리학
위험 요인
진단
제6장 환자 동향
제7장 카르티노이드 종양의 역학과 환자 인구
역학 주요 조사 결과
전제와 근거 : 주요 7개국
역학 시나리오 : 주요 7개국
미국
유럽 5개국
일본역학
제8장 치료 알고리즘, 현재 치료, 의료 행위
제9장 미충족 요구
제10장 카르티노이드 종양 치료의 주요 평가항목
제11장 출시 제품
제12장 새로운 치료법
제13장 카르티노이드 종양 : 주요 7개국 시장 분석
제14장 속성 분석
제15장 주요 7개국 : 시장 전망
미국 : 시장 규모
유럽 5개국 : 시장 규모와 전망
독일 : 시장 규모
프랑스 : 시장 규모
이탈리아 : 시장 규모
스페인 : 시장 규모
영국 : 시장 규모
일본 : 시장 규모
제16장 카르티노이드 종양 접근 및 상환 개요
제17장 KOL(Key Opinion Leader)의 견해
제18장 시장 성장 촉진요인
제19장 시장 성장 억제요인
제20장 부록
제21장 DelveInsight의 서비스 내용
제22장 면책사항
제23장 DelveInsight에 대해
LSH
영문 목차
영문목차
DelveInsight's "Carcinoid Tumor - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Carcinoid Tumor, historical and forecasted epidemiology as well as the Carcinoid Tumor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Carcinoid Tumor market report provides current treatment practices, emerging drugs, Carcinoid Tumor market share of the individual therapies, current and forecasted Carcinoid Tumor market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Carcinoid Tumor treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered:
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2020-2034
Carcinoid Tumor Disease Understanding and Treatment Algorithm
The DelveInsight Carcinoid Tumor market report gives a thorough understanding of the Carcinoid Tumor by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Carcinoid Tumor.
Treatment
It covers the details of conventional and current medical therapies available in the Carcinoid Tumor market for the treatment of the condition. It also provides Carcinoid Tumor treatment algorithms and guidelines in the United States, Europe, and Japan.
Carcinoid Tumor Epidemiology
The Carcinoid Tumor epidemiology division provide insights about historical and current Carcinoid Tumor patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Carcinoid Tumor epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.
Country Wise-Carcinoid Tumor Epidemiology
The epidemiology segment also provides the Carcinoid Tumor epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Carcinoid Tumor Drug Chapters
Drug chapter segment of the Carcinoid Tumor report encloses the detailed analysis of Carcinoid Tumor marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Carcinoid Tumor clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Marketed Drugs
The report provides the details of the marketed product available for Carcinoid Tumor treatment.
Carcinoid Tumor Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Carcinoid Tumor treatment.
Carcinoid Tumor Market Outlook
The Carcinoid Tumor market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Carcinoid Tumor market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Carcinoid Tumor market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Carcinoid Tumor market in 7MM is expected to change in the study period 2020-2034.
Key Findings
This section includes a glimpse of the Carcinoid Tumor market in 7MM.
The United States Market Outlook
This section provides the total Carcinoid Tumor market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Carcinoid Tumor market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Carcinoid Tumor market size and market size by therapies in Japan is also mentioned.
Carcinoid Tumor Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Carcinoid Tumor market or expected to get launched in the market during the study period 2020-2034. The analysis covers Carcinoid Tumor market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Carcinoid Tumor Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Carcinoid Tumor key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Carcinoid Tumor emerging therapies.
Reimbursement Scenario in Carcinoid Tumor
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SME's opinion working in Carcinoid Tumor domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Carcinoid Tumor market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Carcinoid Tumor Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report:
The report covers the descriptive overview of Carcinoid Tumor, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Carcinoid Tumor epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Carcinoid Tumor are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Carcinoid Tumor market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Carcinoid Tumor market
Report Highlights:
In the coming years, Carcinoid Tumor market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Carcinoid Tumor R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Carcinoid Tumor. Launch of emerging therapies will significantly impact the Carcinoid Tumor market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Carcinoid Tumor
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Carcinoid Tumor Report Insights
Patient Population
Therapeutic Approaches
Carcinoid Tumor Pipeline Analysis
Carcinoid Tumor Market Size and Trends
Market Opportunities
Impact of upcoming Therapies
Carcinoid Tumor Report Key Strengths
11 Years Forecast
7MM Coverage
Carcinoid Tumor Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake
Carcinoid Tumor Report Assessment
Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers
Key Questions:
Market Insights:
What was the Carcinoid Tumor market share (%) distribution in 2020 and how it would look like in 2034?
What would be the Carcinoid Tumor total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Carcinoid Tumor market size during the forecast period (2024-2034)?
At what CAGR, the Carcinoid Tumor market is expected to grow in 7MM during the forecast period (2020-2034)?
What would be the Carcinoid Tumor market outlook across the 7MM during the forecast period (2020-2034)?
What would be the Carcinoid Tumor market growth till 2032, and what will be the resultant market Size in the year 2034?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
What is the disease risk, burden and unmet needs of the Carcinoid Tumor?
What is the historical Carcinoid Tumor patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Carcinoid Tumor in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Carcinoid Tumor?
Out of all 7MM countries, which country would have the highest prevalent population of Carcinoid Tumor during the forecast period (2020-2034)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
What are the current options for the Carcinoid Tumor treatment, along with the approved therapy?
What are the current treatment guidelines for the treatment of Carcinoid Tumor in the USA, Europe, and Japan?
What are the Carcinoid Tumor marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Carcinoid Tumor?
How many therapies are developed by each company for Carcinoid Tumor treatment?
How many are emerging therapies in mid-stage, and late stage of development for Carcinoid Tumor treatment?
What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Carcinoid Tumor therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Carcinoid Tumor and their status?
What are the key designations that have been granted for the emerging therapies for Carcinoid Tumor?
What are the global historical and forecasted market of Carcinoid Tumor?
Reasons to buy:
The report will help in developing business strategies by understanding trends shaping and driving the Carcinoid Tumor market
To understand the future market competition in the Carcinoid Tumor market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Carcinoid Tumor in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Carcinoid Tumor market
To understand the future market competition in the Carcinoid Tumor market
Table of Contents
1. Key Insights
2. Executive Summary of Carcinoid Tumor
3. Competitive Intelligence Analysis for Carcinoid Tumor
4. Carcinoid Tumor: Market Overview at a Glance
4.1. Carcinoid Tumor Total Market Share (%) Distribution in 2020
4.2. Carcinoid Tumor Total Market Share (%) Distribution in 2034
5. Carcinoid Tumor: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Carcinoid Tumor Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Carcinoid Tumor Epidemiology Scenario in the 7MM (2020-2034)
7.4. United States Epidemiology
7.4.1. Carcinoid Tumor Epidemiology Scenario in the United States (2020-2034)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Carcinoid Tumor Epidemiology Scenario in Germany (2020-2034)
7.5.2. France Epidemiology
7.5.2.1. Carcinoid Tumor Epidemiology Scenario in France (2020-2034)
7.5.3. Italy Epidemiology
7.5.3.1. Carcinoid Tumor Epidemiology Scenario in Italy (2020-2034)
7.5.4. Spain Epidemiology
7.5.4.1. Carcinoid Tumor Epidemiology Scenario in Spain (2020-2034)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Carcinoid Tumor Epidemiology Scenario in the United Kingdom (2020-2034)
7.5.6. Japan Epidemiology
7.5.6.1. Carcinoid Tumor Epidemiology Scenario in Japan (2020-2034)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Carcinoid Tumor Treatment and Management
8.2. Carcinoid Tumor Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Carcinoid Tumor Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Carcinoid Tumor: Seven Major Market Analysis
13.1. Key Findings
13.2. Carcinoid Tumor Market Size in 7MM
13.3. Carcinoid Tumor Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Carcinoid Tumor Total Market Size in the United States
15.1.2. Carcinoid Tumor Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Carcinoid Tumor Total Market Size in Germany
15.3.2. Carcinoid Tumor Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Carcinoid Tumor Total Market Size in France
15.4.2. Carcinoid Tumor Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Carcinoid Tumor Total Market Size in Italy
15.5.2. Carcinoid Tumor Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Carcinoid Tumor Total Market Size in Spain
15.6.2. Carcinoid Tumor Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Carcinoid Tumor Total Market Size in the United Kingdom
15.7.2. Carcinoid Tumor Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Carcinoid Tumor Total Market Size in Japan
15.8.3. Carcinoid Tumor Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Carcinoid Tumor
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
The table of contents is not exhaustive; the final content may vary.
